Veracyte (VCYT) to Present Afirma GEC Data at ATA Meeting

September 15, 2016 8:02 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Veracyte, Inc. (Nasdaq: VCYT) announced that external researchers will present six posters that reinforce the role of the Afirma Gene Expression Classifier (GEC) as a new standard of care in thyroid cancer diagnosis at the 86th Annual Meeting of the American Thyroid Association (ATA), being held September 21-25 in Denver. Company scientists will also present data suggesting the potential to further enhance the Afirma GEC's performance by combining the test's proven RNA expression-based capabilities with gene variant and fusion information on a next-generation sequencing (NGS) platform.

"Addressing over-treatment of thyroid cancer is a top priority in this field," said Bonnie Anderson, Veracyte's president and chief executive officer. "The long-term clinical evidence presented at the ATA conference will demonstrate the Afirma GEC's efficacy in helping patients with thyroid nodules avoid surgery they do not need, preserving the critical functions of the thyroid gland and taking costs out of the healthcare system. Additionally, our clinical research program continues to push the limits of what is possible in the diagnosis of thyroid cancer through advances that combine rich RNA sequencing with our core machine-learning technology expertise."

To date, Veracyte has received more than 270,000 fine needle aspiration (FNA) patient samples and has performed over 60,000 Afirma GEC tests on those deemed inconclusive by cytopathology. The genomic test is supported by more than 20 published studies and is included in all of the leading clinical practice guidelines. The Afirma GEC is covered by Medicare and most leading private insurance companies, which collectively represent approximately 185 million Americans.

The following abstracts will be presented during the General Poster Session in the Exhibit Hall of the Sheraton Denver Downtown Hotel:

Title:

Long-Term Follow-Up of Cytologically Indeterminate Nodules with Afirma GEC "Benign" Results (Poster #139)

Presenter:

J.A. Sipos, M.D. (The Ohio State University)

Date/Time*:

Thursday, September 22, 9:45-10:30 a.m. and 3:35-4:15 p.m.

Title:

Towards a Next-Generation GEC with Improved Specificity: Feasibility Analysis Using Machine Learning on a Combination of Gene Expression, Variants and Fusions from a Single Novel Sequencing Platform (Poster #180)

Presenter:

G.C. Kennedy, Ph.D. (Veracyte)

Date/Time:

Friday, September 23, 9:45-10:30 a.m. and 3:35-4:15 p.m.

Title:

Five Year Experience with Afirma Gene Expression Classifier (GEC) at a Southern California Teaching Hospital (Poster #283)

Presenter:

H.M. Huribal, M.D. (Scripps Clinic)

Date/Time:

Saturday, September 24, 9:45-10:30 a.m. and 12:35-1:30 p.m.

Title:

Review of Studies Evaluating the Diagnostic Accuracy of the Afirma Gene Expression Classifier in Indeterminate Thyroid Nodules (Poster #213)

Presenter:

N. Busaidy, M.D. (MD Anderson Cancer Center)

Date/Time:

Friday, September 23, 9:45-10:30 a.m. and 3:35-4:15 p.m.

Title:

More Incidental Thyroid Malignancies Observed in the Lobes with a GEC Suspicious Thyroid Nodule (Poster #240)

Presenter:

A.A. Karasinki, M.D. (Geisinger Health System)

Date/Time:

Friday, September 23, 9:45-10:00 a.m. and 3:35-4:15 p.m.

Title:

The First Canadian Experience with the Afirma Gene Expression Classifier Test (Poster #61)

Presenter:

E. Kay-Rivest, M.D. (McGill University)

Date/Time:

Thursday, September 22, 9:45-10:00 a.m. and 3:35-4:15 p.m.

Title:

Preoperative Ultrasonographic Elastography and the Afirma Gene Expression Classifier in Detecting Thyroid Malignancies (Poster #185)

Presenter:

D. Bu Ali, M.D. (Tulane University)

Date/Time:

Friday, September 23, 9:45-10:30 a.m. and 3:35-4:15 p.m.

* All times are Mountain Daylight Time (MDT)

More information about Veracyte's participation at the ATA conference can be found at www.afirma.com/ata2016.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Add Your Comment